Welcome to our new website! If this is the first time you are logging in on the new site, you will need to reset your password. Please contact us at raps@raps.org if you need assistance.
The regulatory function is vital in making safe and effective healthcare products available worldwide. Individuals who ensure regulatory compliance and prepare submissions, as well as those whose main job function is clinical affairs or quality assurance are all considered regulatory professionals.
Resources, news and special offers to support you and your professional development during this difficult time.
One of our most valuable contributions to the profession is the Regulatory Code of Ethics. The Code of Ethics provides regulatory professionals with core values that hold them to the highest standards of professional conduct.
Your membership opens the door to free learning resources on demand. Check out the Member Knowledge Center for free webcasts, publications and online courses.
Like all professions, regulatory is based on a shared set of competencies. The Regulatory Competency Framework describes the essential elements of what is required of regulatory professionals at four major career and professional levels.
RAPS Convergence is going virtual. Join the brightest minds in regulatory online to gain the latest knowledge in the field in an all-virtual experience with workshops, one-on-one expert sessions, and networking communities.
This year, our European regulatory community will converge online with a fully virtual program that will allow attendees to experience Euro Convergence live online from the safety and comfort of their homes.
RAPS' “how to” guide to developing a comprehensive global regulatory strategy for all types of medical devices. Updated September 2020.
The last exam window of 2020 is currently open. Register by 8 October to take the RAC exam this autumn.
The site navigation utilizes arrow, enter, escape, and space bar key commands. Left and right arrows move across top level links and expand / close menus in sub levels. Up and Down arrows will open main level menus and toggle through sub tier links. Enter and space open menus and escape closes them as well. Tab will move on to the next part of the site rather than go through menu items.
RAPS is closely monitoring developments in the Coronavirus (COVID-19) outbreak. See our public safety page for the latest updates.
Posted 18 February 2015 | By Michael Mezher
In an effort to improve the timeliness and consistency of product information changes, the European Medicines Agency (EMA) is now translating recommendations in all official EU languages, plus Icelandic and Norwegian.
In the EU, pharmaceutical companies are required to provide translations of product information to EMA after a product is authorized. The translations must be made in all official EU languages, including Icelandic and Norwegian.
From time to time, product information must be updated to reflect recommendations made by EMA’s Pharmacovigilance Risk Assessment Committee (PRAC). The recommendations are made following PRAC’s monthly assessment of safety signals, which EMA defines as “information on a new or known adverse event that is potentially caused by a medicine.” PRAC recommendations usually involve making changes to the summary of product characteristics (SmPC) and package leaflet. These changes must be translated for product information in all official EU languages.
Beginning with the January 2015 PRAC recommendations, EMA says it will translate PRAC recommendations into all 24 official EU languages, plus Icelandic and Norwegian within three weeks. The translations will be validated by the individual regulatory agencies for accuracy before being published to the PRAC recommendation page. Translations for the January 2015 meeting are already available in 25 languages (Irish appears to be missing from the list).
EMA says by providing translations of PRAC recommendations, companies will have an easier time applying the recommended changes to their product information in a timely manner. Additionally, the agency says this will cut costs for pharmaceutical companies while increasing the consistency and reliability of product information for patients.
The European Union places great importance on the availability of translated documents for EU citizens. EMA’s new measures have the potential to improve patient safety by streamlining the translation of product information updates.
EMA Press Release
Tags: Safety Signal, Drug information, translation
Regulatory Focus newsletters
All the biggest regulatory news and happenings.